HOXA9 and acute myeloid leukemia: In patients with DNMT3A gene mutations associated with worse outcomes and HOXA9 over-expression, decitabine treatment is associated with higher levels of complete remission in comparison with AML patients having wild-type DNMT3A, suggesting that AML patients with low DNMT3A activity due to those loss-of-function mutations benefit from treatment with hypomethylating agents such as decitabine [212].